Eyebot, a startup providing a 90-second imaginative and prescient check kiosk that delivers doctor-verified glasses prescriptions, has secured $20 million in Collection A funding.
The Boston-based startup, based in 2021, streamlines how individuals entry imaginative and prescient care by eliminating conventional obstacles, akin to appointment delays, restricted accessibility, complicated insurance coverage necessities, and price.
Its kiosks, already present in malls, universities, retail shops, pharmacies, grocery chains, colleges, and airports, ship a free, 90-second imaginative and prescient check. In keeping with the corporate, every check generates a prescription that’s then reviewed and accredited by licensed eye medical doctors, guaranteeing quick, handy, and dependable prescriptions.
The brand new funding, which brings Eyebot’s complete funding to greater than $30 million, comes roughly a yr after the startup raised its seed spherical in June 2024. Since then, the startup has carried out greater than 45,000 free imaginative and prescient checks and is on monitor to ship over half one million yearly, it says.
“Since our seed spherical, the shift has been dramatic. We’ve gone from piloting to partnering with among the largest corporations within the U.S., launching kiosks everywhere in the nation, and delivering tens of hundreds of imaginative and prescient checks,” Matthias Hofmann, co-founder and CEO of Eyebot, instructed TechCrunch. “Income is scaling and our workforce has doubled in dimension. Most significantly, we’ve confirmed the mannequin works: individuals are utilizing Eyebot, medical doctors are validating the outcomes, and retailers are excited concerning the visitors it drives.”
What units Eyebot aside, Hofmann mentioned, is its mixture of comfort and medical assurance. Each check is reviewed by a physician, and all prescriptions are issued underneath scientific supervision. If check outcomes point out something uncommon, sufferers are referred for in-person, complete exams. That steadiness of velocity plus scientific oversight earns belief, he says.
“At our mall areas, we’ve seen shocking uptake from mother and father with youngsters,” Hofmann mentioned. “They’ll cease between shops, attempt Eyebot — generally even whereas holding their youngsters’ arms — and depart with a prescription in simply a few minutes.”
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Convincing conventional eye care suppliers to embrace a tech-first strategy has confirmed troublesome. Early skepticism ran deep: medical doctors fearful about accuracy, whereas sufferers questioned whether or not a course of so quick might be dependable, in response to Hofmann. He says that hesitancy eased as soon as suppliers realized that have medical doctors overview each end result, many with greater than a decade of expertise.
Eyebot is within the early phases of commercialization. Its imaginative and prescient check is obtainable free to customers, and if a prescription is required, one of many firm’s medical doctors verifies it for a payment. Moreover, the corporate leases its kiosks to optical retailers, eyewear manufacturers, and impartial practices.
With the Collection A, the corporate plans to scale kiosk deployment and develop its workforce throughout product, scientific operations, and business progress, the CEO mentioned.
The most recent spherical was led by Common Catalyst and included participation from returning buyers AlleyCorp, Baukunst, Village International, Humba Enterprise, Ravelin, and Ubiquity Ventures.
